In their paper, Valdas Jurkauskas and Xiaoyong Fu of STA
Pharmaceuticals address the fact that manufacturing
process throughput optimisation has become a necessity
rather than an option. Only having high product yield,
volumetrically efficient process and shortest possible
production cycle time will enable the sponsor to withstand
future increase in labour and utilities costs and reduce the
probability of complex, expensive and risky post-approval
changes.